Sucam

Quick links to important sections

Sucam

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sucam

What is Sucam? Definition, Composition, and Form

Property Description
Active ingredient Pinaverium Bromide
Form Film-coated tablets
Pharmacological class Selective Calcium Channel Antagonist, Antispasmodic Agent
General purpose Management of intestinal spasm and visceral discomfort
Origin Synthetic compound

Sucam is a prescription-only medicine and a synthetic compound intended for the oral administration route, supplied as film-coated tablets. The preparation is chemically defined by its single active ingredient, Pinaverium Bromide, a molecule categorized as a quaternary ammonium compound. As a single-component product, Sucam primarily consists of Pinaverium Bromide alongside the standard pharmaceutical excipients required to create the solid dosage form. Its positioning focuses specifically on adults experiencing discomfort related to functional gastrointestinal disorders.


Sucam's Classification: A Selective Antispasmodic Agent

Pharmacologically, Sucam is classified as a Selective Calcium Channel Antagonist and an Antispasmodic Agent (or spasmolytic). This designation indicates its primary action is concentrated on controlling the excessive, involuntary contractions of the intestinal smooth muscle.

Pinaverium Bromide exerts this effect by acting specifically on the L-type voltage-dependent calcium channels found in the gut wall. By selectively blocking the movement of calcium ions into these muscle cells, the drug inhibits the signaling process that initiates muscle contraction. Pinaverium Bromide selectively relieves spasms and regulates motility in the gastrointestinal tract. This clinically recognized selective action is what differentiates it from less specific smooth muscle relaxants. This targeted physiological action serves the general therapeutic purpose of promoting the reduction of excessive spasms and mitigating the associated visceral discomfort, providing relief in scenarios like managing routine intestinal hyperactivity.

What side effects are possible with Sucam?

Possible Side Effects and Safety Information

The safety profile of Sucam (Pinaverium Bromide) is formally documented based on government regulatory standards, classifying potential effects by frequency and the body system affected.

Adverse Reactions by System and Frequency

Adverse reactions primarily affect the Gastrointestinal and Skin systems. Most reactions are considered Common (may affect up to 1 in 10 people), including abdominal pain, constipation, nausea, and headache. Uncommon reactions (up to 1 in 100) include diarrhea and somnolence (drowsiness).

System-Organ Class Examples of Documented Reactions
Gastrointestinal disorders Abdominal pain, Nausea, Constipation, Dry mouth, Dyspepsia, Vomiting, Dysphagia, Esophageal lesion
Skin and subcutaneous tissue disorders Rash, Pruritus (itching), Urticaria, Erythema
Immune system disorders Hypersensitivity reactions

Serious Safety Considerations

Regulatory documentation highlights the potential for Systemic Hypersensitivity Reactions, including severe allergic events such as Anaphylactic Shock and Angioedema. A specific local safety concern is the risk of Esophageal Lesion, a possible injury noted to occur if the tablet is not properly administered.

Safety Restrictions and Specific Populations

Use of Sucam is contraindicated if a person has a known Hypersensitivity to Pinaverium Bromide or its inactive ingredients, or specific hereditary metabolic disorders. The medicine is not recommended for the pediatric population as safety and efficacy have not been established in children. Furthermore, its safety is not established during pregnancy or breast-feeding, limiting its use in these populations.

Overdose and Emergency Response

Sucam Overdose and when to seek help — official regulatory information

Domain Official Regulatory Statement
Documented overdose presentations Gastrointestinal complaints, including extbfdiarrhea, extbfflatulence, and extbfnausea, are the primary documented clinical manifestations.
Physiological systems affected Effects are limited to the extbfgastrointestinal tract. No specific severe, life-threatening extbfsystemic effects are explicitly noted in the overdose section.
Dose-related factors Overdosage in man with daily doses up to extbf1,200 mg has been reported to induce no undesirable effects other than the documented gastrointestinal manifestations.
Emergency-response statements Management consists of extbfsymptomatic treatment because extbfno specific antidote is known.
When immediate medical help is required Users are mandated to extbfseek immediate medical attention and extbfcontact a regional extbfPoison Control Centre or extbfhospital emergency department immediately, extbfeven if there are no symptoms.

Overdose Classifications

Classification Official Regulatory Statement
Severity classification The official profile indicates a extbflow intrinsic acute toxicity, with symptoms generally confined to the gastrointestinal system.
Regulatory basis The information is based on official prescribing documents from extbfnational European health agency SmPC and the extbfHealth Canada Product Monograph.

Official Overdose Statements: Official regulatory documents confirm that manifestations are limited to gastrointestinal symptoms such as diarrhea, flatulence, and nausea. No specific antidote is known, requiring management to focus strictly on supportive and symptomatic measures.

Connection to the overall overdose profile: Regulators define the overdose profile based on the drug's high tolerance and the localized nature of the symptoms. Immediate medical contact is mandated for all suspected overdoses to ensure professional monitoring and management, regardless of the patient's initial symptomatic presentation.

Therapeutic Uses of Sucam

Quick Facts: Uses of Sucam

Condition
Support for healing duodenal ulcers
Maintenance treatment for duodenal ulcers

What Sucam Treats: Main Uses and Benefits

Sucam (sucralfate) is used as a prescription medication to address certain gastrointestinal conditions. Its primary therapeutic application is in the short-term management of active duodenal ulcers. Duodenal ulcers are open sores that develop in the lining of the small intestine, specifically the duodenum.

Following the resolution of an acute duodenal ulcer, Sucam may also be indicated for maintenance therapy. The goal of this continued treatment is to assist in preventing the recurrence of duodenal ulcers after initial healing has been established.

In these contexts, the medication provides a protective action for the compromised mucosal surface. The treatment is intended to create conditions that facilitate the body's natural processes to support the healing of the ulcerated tissue. The indicated uses for Sucam focus on these two primary applications within the gastrointestinal tract.


Note: The use of Sucam must be based on a clinician’s recommendation, following a confirmed diagnosis. This content is for informational purposes only and is not a substitute for medical advice.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sucam?

Category Official Regulatory Statement
Populations for whom use is allowed Adult patients are eligible for the short-term treatment of active duodenal ulcers and for maintenance therapy.
Populations for whom use is contraindicated The medicine is contraindicated in patients with a known history of hypersensitivity to sucralfate or any of the product’s excipients.
Age-related eligibility rules Use in the pediatric population is not established, as safety and effectiveness have not been determined. Dose selection for elderly patients should be cautious, reflecting the greater frequency of reduced kidney function.
Condition-specific eligibility rules Use with caution is required in patients with chronic renal failure or those receiving dialysis, due to the risk of aluminum accumulation. Caution is also advised in patients with diabetes and those with conditions predisposing to bezoar formation, such as delayed gastric emptying.
Pregnancy and lactation eligibility status Use during pregnancy is conditional and should only occur if clearly needed, as adequate human studies are lacking. It is unknown if the drug is excreted in human breast milk.

The regulatory documents define who can and cannot use Sucam by establishing one absolute exclusion (hypersensitivity). All other population limitations are defined as precautions, requiring caution in adult patients with impaired renal function and the elderly. Use in children is not formally permitted because safety and effectiveness in the pediatric population are not established by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding the use of Sucam with other products and procedures that affect the body's clearance mechanisms or metabolism.

Documented Interaction Categories

Interaction Domain Practical Regulatory Implication
Iodinated Contrast Media Requires temporary discontinuation of Sucam immediately before and after the procedure due to the risk of issues related to kidney function, which can lead to drug accumulation.
Excessive Alcohol Intake Patients must be advised against acute or chronic excessive consumption as this potentiates the drug's effect on lactate metabolism, a clinically significant safety concern.
OCT/MATE Inhibitors Co-administration with medications that inhibit Organic Cation Transporters (OCTs) or Multidrug and Toxin Extrusion (MATE) transporters may increase the amount of Sucam in the bloodstream.

Specific Interacting Agents

Medicines explicitly cited as inhibitors of the renal transport system (OCT/MATE) that may increase Sucam exposure include cimetidine, pyrimethamine, and cephalexin. When these specific agents are co-administered, the official labeling may necessitate close clinical monitoring and potential adjustment of the Sucam dose to mitigate the risk of increased systemic concentrations. The overall interaction profile is structured around minimizing the potentiation of metabolic complications and preventing drug accumulation resulting from interference with renal clearance pathways, which are the two main high-level regulatory concerns.

Mechanism of Action

Selective L-Type Calcium Channel Blockade

The primary mechanism of action involves the highly selective antagonism of L-type Voltage-Dependent Calcium Channels ( L-VDCCs) on the intestinal smooth muscle cells. By inhibiting the voltage-gated influx of extracellular calcium ions ( Ca^2+), the drug interrupts the fundamental cellular process of excitation-contraction coupling, which directly results in the inhibition of smooth muscle fiber shortening.


Targeted Peripheral Spasmolysis

The drug's chemical structure as a quaternary ammonium compound dictates its action is restricted to the peripheral GI tract due to minimal systemic absorption. This physicochemical characteristic results in a localized, high-concentration effect that is primarily dedicated to reducing muscle excitability in the gut wall, restricting mechanistic influence primarily to the gastrointestinal smooth muscle tissue.


Modulation of Intestinal Muscle Tone

This selective blockade cascade leads to the core physiological outcome: the reduction of excessive muscle tone and involuntary contractions within the intestinal wall. The resulting physiological change in muscle activity contributes to the suppression of hypermotility patterns.

Dosage and Administration Information

How to Use Sucam: Official Administration Guidelines

This section outlines the standardized rules for taking Sucralfate (Sucam), defining the required administration route, dosage patterns, and specific timing conditions.


Administration Scope

Instruction Entity Official Guideline (Sucralfate)
Route of administration Oral (by mouth)
Dosing schedule Active Duodenal Ulcer: 1 gram four times daily (QID). Maintenance Therapy: 1 gram twice daily (BID).
Timing in relation to meals Must be administered on an empty stomach, typically one hour before meals and at bedtime.
Preparation requirements Oral Suspension: The container must be shaken well before measuring and administration.
Age-group administration rules Older Adults: Dose selection should start at the low end of the dosing range. Pediatric Patients: Safety and effectiveness have not been established.
Special procedural conditions Antacids: Avoid taking antacids within 30 minutes before or after Sucralfate. Other Oral Medications: Other oral drugs should generally be taken 2 hours before or 2 hours after Sucralfate.
Treatment Duration Active Ulcer: Up to 4 to 8 weeks, or until healing is confirmed. Maintenance: Up to 12 months in clinical studies.

Official Usage Protocol

Sucralfate is administered orally in a time-dependent manner to ensure the medication contacts the gastrointestinal lining optimally. The prescribed dose is either 1 gram four times daily for active treatment or 1 gram twice daily for maintenance. This schedule is constrained by the rule that the medication must be taken on an empty stomach, separating it from food and necessitating a 30-minute buffer from antacids and a 2-hour buffer from most other oral medications. These administration requirements structure the entire use protocol, ensuring consistency with established usage protocols.

Recent Clinical Evidence

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that is documented in research as being used to manage pain and inflammation associated with various conditions. It belongs to the class of selective cyclooxygenase-2 (COX-2) inhibitors.


Approved Indications and Effectiveness

The primary uses of celecoxib documented in research are the management of pain and inflammation in conditions such as osteoarthritis (OA), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), and acute pain.

Clinical evidence supports the observed role of celecoxib in managing symptoms and demonstrating an association with improved physical function in these conditions. Specific findings include:

  • For OA, clinical studies observed an association with reduced joint pain and stiffness.
  • For RA, studies report reductions in joint pain and swelling as part of a treatment regimen.
  • For AS, studies document an association with reduced measures of disease activity, including back pain and stiffness.

Cardiovascular and Gastrointestinal Safety Research

Research indicates that, like other NSAIDs, celecoxib is associated with a risk of serious cardiovascular (CV) events, including myocardial infarction and stroke. This is a documented class-wide finding for all NSAIDs. The large-scale PRECISION trial (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen) found that at approved doses, the CV risk associated with celecoxib was non-inferior (i.e., not greater) than the CV risk observed with prescription doses of ibuprofen and naproxen in patients with arthritis and existing CV risk factors.

Studies comparing celecoxib to non-selective NSAIDs document a lower incidence of complicated gastrointestinal (GI) events (perforations, ulcers, or bleeds). In the PRECISION trial, celecoxib was associated with significantly fewer GI events than either ibuprofen or naproxen.

Frequently Asked Questions (FAQ)

Common questions about Sucam (FAQ)

Q: What is the difference between Sucam and other similar medicines?

Official sources describe Sucam (Pinaverium Bromide) as a Selective Calcium Channel Antagonist and a quaternary ammonium compound. Official information suggests its action is primarily concentrated on the smooth muscle of the gastrointestinal tract. This targeted action is due to the drug’s physical properties, which limit its systemic absorption into the rest of the body.


Q: Is it safe to drink alcohol while taking Sucam?

Regulatory documents advise against both acute (sudden) and chronic (long-term) excessive consumption of alcohol while using Sucam. This caution is based on regulatory information, which notes excessive alcohol intake may potentiate the drug’s effect on lactate metabolism.


Q: Can older people use Sucam?

Regulatory guidelines state that Sucam is an option for older adults. However, official information advises that dose selection should be cautious, often suggesting starting at the low end of the dosing range. This approach reflects the greater frequency of reduced kidney function in this population.


Q: What are the official warnings about taking Sucam?

Official documents indicate the medicine is contraindicated in patients with a known history of hypersensitivity (severe allergy) to the drug or its components. There is also a specific precaution regarding the risk of an esophageal lesion (injury to the throat lining) if the tablet is not properly administered. Caution is also advised for elderly people and those with chronic renal (kidney) problems.


Q: Is it normal to feel a mild headache when first starting Sucam?

Official regulatory information lists headache as a Common side effect. This means headache is among the reactions that may affect up to 1 in 10 people taking the medicine. Experiencing a mild headache is noted in the drug’s official safety profile.


Q: Can I take pain relievers like ibuprofen with Sucam?

Regulatory guidelines suggest that most other oral medications, including pain relievers like ibuprofen, be taken either 2 hours before or 2 hours after taking Sucam. This procedural separation is intended to ensure that the absorption and effectiveness of the other medicine are not interfered with.


Q: Is there a specific time of day that is better for taking Sucam?

Official instructions require that Sucam be taken on an empty stomach. For most people, this requirement dictates a schedule that includes doses one hour before meals and a final dose at bedtime to align with the regulatory requirement that the drug be taken on an empty stomach.


Q: Can Sucam affect sleep?

Official documentation lists somnolence, or drowsiness, as an Uncommon adverse reaction. This means that drowsiness may affect up to 1 in 100 people taking the medicine, and this potential effect is noted in the adverse reaction profile.


Q: Is Sucam a type of antibiotic?

No. Sucam is officially classified as a Selective Calcium Channel Antagonist and an Antispasmodic Agent. This designation indicates its primary function is to relieve muscle spasms, and it is not classified as an antibiotic for bacterial infections.


Q: Why do some people say Sucam makes them tired?

The reason some people may feel tired is reflected in the official safety profile. Regulatory documents acknowledge somnolence, or drowsiness, as an uncommon side effect. This means the feeling of being tired or drowsy is a documented adverse reaction that may occur in up to 1 in 100 people using Sucam.


Q: Has Sucam been tested in pregnant women?

Official regulatory information indicates that adequate human studies on the use of Sucam during pregnancy are currently lacking. Therefore, its use is conditional and should only occur if clearly needed, given that adequate human studies are lacking.


Q: What kind of research supports the use of Sucam?

The use of Sucam is grounded in published pharmacological studies and systematic reviews. This evidence confirms the drug's selective action in relieving muscle spasms and regulating motility within the gastrointestinal tract.


Q: Are there certain health conditions that mean someone cannot take Sucam?

The medicine is contraindicated if a person has a known history of hypersensitivity (severe allergy) to the drug. Caution is also advised for conditions that predispose a person to bezoar formation (e.g., delayed gastric emptying) and for patients with chronic renal failure (kidney problems).


Q: Does Sucam affect mental clarity or focus?

The safety profile lists somnolence (drowsiness) as an uncommon effect of Sucam. This potential for drowsiness is a central nervous system-related effect that may impact a person’s mental clarity or focus.


Q: Are there specific food or drink restrictions while on Sucam?

The primary requirement for taking Sucam is that the tablets be taken on an empty stomach. Additionally, official guidance cautions against excessive alcohol consumption while using the drug.


Q: Do official sources mention any long-term effects of taking Sucam?

Clinical studies have examined the drug for up to 12 months for maintenance therapy. Official documentation typically does not define 'long-term effects' beyond the adverse event profile observed during trials of defined duration.


Q: Is it okay to drive or operate machinery while on Sucam?

Regulatory information notes the potential for somnolence (drowsiness) as an uncommon adverse reaction. The potential for somnolence is a factor noted for individuals engaging in activities that require full attention, such as driving or operating machinery.


Q: Does Sucam change how other medications are absorbed?

Yes. The official administration protocol requires a 2-hour buffer between taking Sucam and most other oral medications. This guideline is in place specifically to prevent Sucam from interfering with the absorption of those other drugs.


Q: Are there any reports of Sucam causing skin rashes?

Yes. Official documentation lists several skin reactions, including rash, pruritus (itching), urticaria (hives), and erythema (redness). These are documented under the category of skin and subcutaneous tissue disorders in the adverse reaction profile.


Q: Does taking Sucam require any change in diet?

The official guidance does not list any mandatory dietary changes. The main requirement related to consumption is the need to take the medicine on an empty stomach. The only other consumption-related caution is against excessive alcohol intake.


Q: Is Sucam used for acute issues or long-term management?

Sucam is officially prescribed for both acute and long-term uses. It is used for the short-term treatment of active duodenal ulcers (up to 4–8 weeks) and for long-term maintenance therapy (up to 12 months in studies).


Q: Are there any specific lifestyle changes recommended when starting Sucam?

Official guidance cautions against excessive alcohol intake. It also strictly regulates the timing of taking antacids and other oral medicines, requiring specific time separation.

How should Sucam be stored and disposed of?

How to Store and Dispose of Sucam (Sucralfate Tablets)

Sucam tablets must be stored at controlled room temperature, maintaining a range between 20 C and 25 C (68 F and 77 F), according to official prescribing information. Brief temperature excursions between 15 C and 30 C are permitted. The container must be kept tightly closed to ensure the product is protected from moisture.

Child Safety and Disposal

It is mandatory to keep this and all drugs out of the reach of children. Unused or expired Sucam tablets must be disposed of in accordance with applicable local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sucam found in:

A-Z Index: